Answers are grounded in this paper and cite their sources.
Observational data reveal immune dysregulation linked to angioedema in IS patients treated with R-tPA, suggesting new insights into its pathophysiology.
These preliminary data suggest that R-tPA-related angioedema may result from abnormal immune cell activation, leading to increased release of vasoactive mediators. This immune dysregulation may contribute to the pathophysiology of angioedema in susceptible IS patients treated with R-tPA.
No takes yet. Share an insight, caveat, or question.
Palestra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: